Detalles de la búsqueda
1.
A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
Gynecol Oncol
; 185: 83-94, 2024 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38377762
2.
Dedicated financial hardship screening adds value to routine distress screening among gynecologic cancer patients.
Gynecol Oncol
; 183: 53-60, 2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38518528
3.
Evolving roles of activins and inhibins in ovarian cancer pathophysiology.
Am J Physiol Cell Physiol
; 324(2): C428-C437, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36622068
4.
TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
Gynecol Oncol
; 178: 44-53, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37748270
5.
Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
Oncologist
; 27(3): 167-174, 2022 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274707
6.
Sequential modulation of the Wnt/ß-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.
Gynecol Oncol
; 164(1): 170-180, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34844776
7.
High-intermediate risk endometrial cancer: moving toward a molecularly based risk assessment profile.
Int J Clin Oncol
; 27(2): 323-331, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35038071
8.
Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study.
Gynecol Oncol
; 163(1): 85-92, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34372972
9.
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II.
Gynecol Oncol
; 160(3): 827-834, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33451724
10.
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.
Gynecol Oncol
; 160(3): 817-826, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33516529
11.
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecol Oncol
; 161(2): 496-501, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33637348
12.
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Gynecol Oncol
; 156(2): 301-307, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31870556
13.
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
Gynecol Oncol
; 157(3): 578-584, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32265057
14.
A Ketogenic Diet Is Acceptable in Women with Ovarian and Endometrial Cancer and Has No Adverse Effects on Blood Lipids: A Randomized, Controlled Trial.
Nutr Cancer
; 72(4): 584-594, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31352797
15.
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1.
Cancer Immunol Immunother
; 68(12): 2081-2094, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31720815
16.
The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.
Cancer Immunol Immunother
; 68(2): 175-188, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30334128
17.
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
Gynecol Oncol
; 155(2): 201-206, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31522837
18.
Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.
Future Oncol
; 15(28): 3267-3281, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31394933
19.
The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Cancer
; 124(24): 4657-4666, 2018 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30423192
20.
Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.
Oncologist
; 23(12): 1533-1545, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30139839